230 related articles for article (PubMed ID: 30717901)
21. Initial radioiodine administration: when to use it and how to select the dose.
Esposito G
Endocrinol Metab Clin North Am; 2014 Jun; 43(2):385-400. PubMed ID: 24891168
[TBL] [Abstract][Full Text] [Related]
22. [The basis for radioiodine therapy in differentiated thyroid cancer].
Haldemann AR
Ther Umsch; 1999 Jul; 56(7):403-7. PubMed ID: 10434780
[TBL] [Abstract][Full Text] [Related]
23. [Recombinant human TSH stimulation in radioiodine treatment of disseminated differentiated thyroid cancer--update of current and our own experiences].
Hasse-Lazar K; Handkiewicz-Junak D; Roskosz J; Szpak-Ulczok S; Krajewska J; Jurecka-Lubieniecka B; Jarzab B
Endokrynol Pol; 2006; 57(4):445-50. PubMed ID: 17006851
[TBL] [Abstract][Full Text] [Related]
24. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
[TBL] [Abstract][Full Text] [Related]
25. Radioiodine treatment for malignant thyroid disease.
Berg G
Acta Oncol; 2006; 45(8):1041-5. PubMed ID: 17118836
[TBL] [Abstract][Full Text] [Related]
26. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
[TBL] [Abstract][Full Text] [Related]
27. [Indications for adjuvant therapy of thyroid cancer with radioiodine therapy].
Jarzab B
Wiad Lek; 2001; 54 Suppl 1():254-65. PubMed ID: 12182034
[TBL] [Abstract][Full Text] [Related]
28. Radioiodine ablation in low-risk thyroid cancer.
Orlov S; Freeman JL; Walfish PG
N Engl J Med; 2012 Aug; 367(7):672; author reply 673-5. PubMed ID: 22894582
[No Abstract] [Full Text] [Related]
29. Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer.
Handkiewicz-Junak D; Gawlik T; Rozkosz J; Puch Z; Michalik B; Gubala E; Krajewska J; Kluczewska A; Jarzab B
Eur J Endocrinol; 2015 Dec; 173(6):873-81. PubMed ID: 26423095
[TBL] [Abstract][Full Text] [Related]
30. Radioiodine therapy in differentiated thyroid cancer: a nuclear medicine perspective.
Clarke SE
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):430-7. PubMed ID: 20537878
[No Abstract] [Full Text] [Related]
31. Radioiodine therapy of metastatic lesions of differentiated thyroid cancer.
Luster M; Hänscheid H; Freudenberg LS; Verburg FA
J Endocrinol Invest; 2012; 35(6 Suppl):21-9. PubMed ID: 23014070
[TBL] [Abstract][Full Text] [Related]
32. Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
Schlumberger M; Catargi B; Borget I; Deandreis D; Zerdoud S; Bridji B; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Dejax C; Toubert ME; Leboulleux S; Ricard M; Benhamou E;
N Engl J Med; 2012 May; 366(18):1663-73. PubMed ID: 22551127
[TBL] [Abstract][Full Text] [Related]
33. Radioactive Iodine Therapy in Differentiated Thyroid Cancer: 2020 Update.
Ciarallo A; Rivera J
AJR Am J Roentgenol; 2020 Aug; 215(2):285-291. PubMed ID: 32551904
[No Abstract] [Full Text] [Related]
34. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States.
Wang TS; Cheung K; Mehta P; Roman SA; Walker HD; Sosa JA
J Clin Endocrinol Metab; 2010 Apr; 95(4):1672-80. PubMed ID: 20139234
[TBL] [Abstract][Full Text] [Related]
35. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
36. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.
Robbins RJ; Larson SM; Sinha N; Shaha A; Divgi C; Pentlow KS; Ghossein R; Tuttle RM
J Nucl Med; 2002 Nov; 43(11):1482-8. PubMed ID: 12411552
[TBL] [Abstract][Full Text] [Related]
37. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.
Hartung-Knemeyer V; Nagarajah J; Jentzen W; Ruhlmann M; Freudenberg LS; Stahl AR; Bockisch A; Rosenbaum-Krumme SJ
Ann Nucl Med; 2012 Nov; 26(9):723-9. PubMed ID: 22802008
[TBL] [Abstract][Full Text] [Related]
38. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
39. Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer.
Sgouros G
J Nucl Med; 2005 May; 46(5):899-900; author reply 901. PubMed ID: 15872367
[No Abstract] [Full Text] [Related]
40. Role of radioactive iodine for adjuvant therapy and treatment of metastases.
Jonklaas J
J Natl Compr Canc Netw; 2007 Jul; 5(6):631-40. PubMed ID: 17623614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
